Bristol Gears Up For Orencia Launch With Creation Of Immunoscience Unit
Executive Summary
Bristol-Myers Squibb has created an immunoscience business unit to support the upcoming launch of Orencia (abatacept) for rheumatoid arthritis, U.S. Pharmaceuticals President Anthony Hooper said
You may also be interested in...
Bristol Will Use One Distributor To Ensure Patient Access For Orencia Launch
Bristol-Myers Squibb is launching its rheumatoid arthritis treatment Orencia (abatacept) through a sole distributor to ensure patient access while the firm works to expand its manufacturing capacity
Orencia Promos To Focus On Docs, Disease Awareness; No Branded DTC For Now
Professional education efforts will be the centerpiece of Bristol-Myers Squibb's late-February launch of the rheumatoid arthritis treatment Orencia (abatacept) under the company's voluntary direct-to-consumer advertising moratorium for new products
Bristol Will Use One Distributor To Ensure Patient Access For Orencia Launch
Bristol-Myers Squibb is launching its rheumatoid arthritis treatment Orencia (abatacept) through a sole distributor to ensure patient access while the firm works to expand its manufacturing capacity